Effects of two dosages of subcutaneous low molecular weight heparin (Parnaparin) and of unfractionated heparin on fibrin formation and lipolysis in acute myocardial infarction

This publication has 12 references indexed in Scilit:

• Guidelines for the early management of patients with acute myocardial infarction
  Journal of the American College of Cardiology, 1990
• Coronary Thrombolysis: Streptokinase or Recombinant Tissue-Type Plasminogen Activator?
  Annals of Internal Medicine, 1990
• Antithrombotic therapy in acute myocardial infarction: Prevention of venous, left ventricular and coronary artery thromboembolism
  The American Journal of Cardiology, 1989
• Comparison of High-Dose with Low-Dose Subcutaneous Heparin to Prevent Left Ventricular Mural Thrombosis in Patients with Acute Transmural Anterior Myocardial Infarction
  New England Journal of Medicine, 1989
• The limited importance of factor Xa inhibition to the anticoagulant property of heparin in thromboplastin-activated plasma
  Blood, 1988
• A Randomized Controlled Trial of a Low-Molecular-Weight Heparin (Enoxaparin) to Prevent Deep-Vein Thrombosis in Patients Undergoing Elective Hip Surgery
  New England Journal of Medicine, 1986
• Fibrin formation and platelet aggregation in patients with acute myocardial infarction: Effects of intravenous and subcutaneous low-dose heparin
  American Heart Journal, 1986
• Fibrinopeptide A and beta thromboglobulin in patients with angina pectoris and acute myocardial infarction
  American Heart Journal, 1984
• Evaluation of an amidolytic heparin assay method: Increased sensitivity by adding purified antithrombin III
  Thrombosis Research, 1977
• Assay of heparin in plasma using a chromogenic substrate for activated factor X
  Thrombosis Research, 1976